Print version | PDF version | Send article | RSS feed

Helix Genomics Signs MOU with Cronos Therapeutics UK

30 Mar 2005 - In a major breakthrough in the field of Biotech & Pharmaceutical Contract Research Services, Helix Genomics Pvt. Ltd. (Helix) has signed the MOU with Cronos Therapeutics Ltd. (CTL) United Kingdom. Mentioning the details of the MOU, Dr. Rajani Kanth Vangala, Director& CSO and In-charge Helix's-UK operations said, "We will be providing the critical Bio-Computational research services and undertake development of a specific Bio-analytical tool for designing Target specific binding modules." Helix will custom build and develop the specific software modules for the designing of compounds for CTL against an undisclosed upfront payment.
 
CTL is a biopharmaceutical company established to develop a novel and groundbreaking class of therapeutics based on the unique and proprietary GeneICE platform. The Company has developed a rapid and cost effective development program to bring this novel class of drugs to the marketplace. First lead compounds have been selected for GeneICE drug development.
 
GeneICE therapeutics can be designed to treat a wide range of diseases. The Company will focus its own development projects in oncology, a field in which the Company has considerable core competence, and will seek licensing or collaborative opportunities in other therapeutic areas.